City
Epaper

Centre’s Rs 15K cr PLI scheme for pharma to boost domestic manufacturing

By IANS | Updated: December 7, 2024 11:20 IST

New Delhi, Dec 7 The Union government has approved a financial outlay of Rs 15,000 crore for the ...

Open in App

New Delhi, Dec 7 The Union government has approved a financial outlay of Rs 15,000 crore for the Production Linked Incentive (PLI) scheme for pharmaceuticals, aimed at boosting domestic manufacturing.

In a written reply to Lok Sabha, Union Minister of State for Chemicals and Fertilizers Anupriya Patel said the government has taken several measures to encourage domestic manufacturing in the pharmaceutical sector. This includes Bulk Drugs and Medical Devices which will help reduce import dependence, boost domestic manufacturing, and attract large investments.

Patel informed that the PLI scheme for the promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (also known as the PLI scheme for Bulk Drugs) has been approved with a financial outlay of Rs. 6,940 crores.

The scheme, which will provide financial incentives for manufacturing notified products, will be carried out from FY 2022-2023 to FY 2028-29.

The PLI scheme for pharmaceuticals, with a financial outlay of Rs. 15,000 crores, for the FY 2022-23 to FY 2027-28 tenure “provides for a financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years”, Patel said.

Under this scheme, Patel noted that high-value pharmaceutical products such as patented/off-patented drugs, biopharmaceuticals, complex generics, anti-cancer drugs, auto-immune drugs, orphan drugs, etc. are manufactured.

Another Rs. 3,420 crore has been assigned for the PLI scheme for promoting domestic manufacturing of medical devices from FY 2022-2023 to FY 2026-27.

It provides an incentive to selected companies at the rate of 5 per cent on incremental sales of medical devices manufactured in India and covered under the four target segments of the scheme, for five years.

“Under this scheme, high-value medical devices such as linear accelerators, MRI machines, CT-scans, mammograms, C-arms, ultrasound machines, etc are manufactured, which were previously imported into the country,” Patel said.

The scheme allows investment in new plant and machinery, R&D, product registration, and building.

“As of October 2024, a total investment of Rs 33,534 crore has been realised under the scheme and has surpassed the original projected investment of Rs 17,275 crore. An incentive amount of Rs.3,215 crore has been released under the scheme to 45 companies,” the MoS said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalFrom PoK to Balochistan: Rising uprisings signal collapse of Pakistan army’s grip

InternationalThankful for PM Modi backing Gaza peace plan: Israeli envoy Reuven Azar

Other SportsFrom empty stands to roaring crowds: How Women's ODI WCs evolved from 2013 to 2025

BusinessCommunity, Doctors, and Patients Join Hands as SPARSH Hospitals Leads the Beat for Heart Health

BusinessDurga Puja Offers 2025: Best Smartwatch Deals to Buy on EMI

Technology Realted Stories

TechnologyMan Industries shares plunge over 15 pc as SEBI bars top executives from market

TechnologyGovt appoints new chiefs for Union Bank, Central Bank of India

TechnologySpaceX targets 11th test flight of Starship for October 13

TechnologyIndia set for 6.5 pc average growth over next decade: Morgan Stanley

TechnologyS. Korea to launch Nuri space rocket on November 27: KASA